Clinical Trial: A Randomized, Open-label, Blinded Endpoint Assessment Study of Early PCSK9 Inhibitor Administration After Thrombectomy in Patients With Atherosclerotic Acute Ischemic Stroke.

U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07295366) titled 'A Randomized, Open-label, Blinded Endpoint Assessment Study of Early PCSK9 Inhibitor Administration After Thrombectomy in Patients With Atherosclerotic Acute Ischemic Stroke.' on Dec. 07.

Brief Summary: This study (EPOCH-TECT) was a single-center, randomized, open-label, blinded, endpoint-assessing controlled trial conducted at the Affiliated Hospital of Xuzhou Medical University. It aimed to investigate the efficacy and safety of administering the PCSK9 inhibitor evolocumab early (within 6 hours) after successful thrombectomy in patients with atherosclerotic large vessel occlusive stroke. The study planned to enroll 60 patients, wh...